How big is Kronos Bio, Inc.?

As of Jun 18, Kronos Bio, Inc. has a market capitalization of 53.96 million and reported net sales of 9.19 million with a net profit of -64.48 million over the last four quarters. Shareholder's funds are 87.58 million, and total assets are 124.55 million.

As of Jun 18, Kronos Bio, Inc. has a market capitalization of 53.96 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the sum of net sales for the latest four quarters is 9.19 million, while the sum of net profit for the same period is -64.48 million.<BR><BR>As of Dec 24, the shareholder's funds amount to 87.58 million, and total assets are reported at 124.55 million.

What does Kronos Bio, Inc. do?

Kronos Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing cancer therapeutics targeting dysregulated transcription, with a market capitalization of approximately $53.96 million. As of March 2025, it reported net sales of $2 million and a net loss of $8 million.

Overview:<BR>Kronos Bio, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of cancer therapeutics targeting dysregulated transcription, operating in the Pharmaceuticals & Biotechnology industry with a micro-cap market capitalization.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 2 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -8 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 53.96 Million (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -1.20 <BR>Return on Equity: -56.07% <BR>Price to Book: 0.68<BR><BR>Contact Details:<BR>Address: 1300 S. El Camino Real, Suite 300, SAN MATEO CA: 94402 <BR>Tel: 1 212 8717920 <BR>Fax: 1 302 6365454 <BR>Website: https://kronosbio.com/

Should I buy, sell or hold Kronos Bio, Inc.?

Who are in the management team of Kronos Bio, Inc.?

As of March 2022, the management team of Kronos Bio, Inc. includes Dr. Arie Belldegrun as Chairman of the Board and Dr. Norbert Bischofberger as President, CEO, and Director.

As of March 2022, the management team of Kronos Bio, Inc. includes Dr. Arie Belldegrun, who serves as the Chairman of the Board, and Dr. Norbert Bischofberger, who is the President, Chief Executive Officer, and a Director.

Is Kronos Bio, Inc. overvalued or undervalued?

As of May 10, 2023, Kronos Bio, Inc. is considered risky and overvalued due to its negative return on equity and poor performance compared to peers, with a one-year return of -15.38% versus the S&P 500's 17.14%.

As of 10 May 2023, the valuation grade for Kronos Bio, Inc. has moved from does not qualify to risky, indicating increased caution regarding its financial health. Based on the available metrics, the company appears to be overvalued. The price-to-book value stands at 0.67, while the EV to EBITDA ratio is 0.88, suggesting that the market may not be pricing in the company's significant losses adequately. Additionally, the return on capital employed (ROCE) is exceptionally high at 310.76%, but this is somewhat misleading given the negative return on equity (ROE) of -56.07%.<BR><BR>In comparison to its peers, Kronos Bio, Inc. has a valuation of -1.1990, while Chimerix, Inc. is at -8.6897, and CytomX Therapeutics, Inc. is rated very attractive with a P/E of 7.4924. This highlights that Kronos is not only underperforming relative to a more attractive competitor but also suggests that its current valuation may not be justified given the negative trends. Over the past year, Kronos Bio has returned -15.38%, significantly underperforming the S&P 500's return of 17.14%, reinforcing the notion that the stock is overvalued in the current market context.

Is Kronos Bio, Inc. technically bullish or bearish?

As of June 3, 2025, Kronos Bio, Inc. exhibits a mildly bearish technical trend with mixed indicators and significant underperformance compared to the S&P 500, showing a 1-week return of -1.41% and a 1-year return of -15.38%.

As of 3 June 2025, the technical trend for Kronos Bio, Inc. has changed from bearish to mildly bearish. The weekly MACD is mildly bullish, while the monthly MACD is also mildly bullish, suggesting some positive momentum. However, the daily moving averages indicate a mildly bearish stance. The Bollinger Bands show a mixed signal with a mildly bullish weekly outlook and a mildly bearish monthly outlook. The KST is bearish on the weekly and mildly bullish on the monthly, and the Dow Theory indicates a bearish monthly trend with no trend on the weekly. The OBV is mildly bullish weekly but mildly bearish monthly.<BR><BR>In terms of performance, Kronos Bio has underperformed the S&P 500 across most periods, with a 1-week return of -1.41% compared to the S&P 500's 1.05%, and a 1-year return of -15.38% against the S&P 500's 17.14%. Overall, the technical stance is mildly bearish, driven by mixed indicators and significant underperformance relative to the benchmark.